Milton Werner
Gründer bei INHIBIKASE THERAPEUTICS, INC.
Vermögen: 2 Mio $ am 30.04.2024
Aktive Positionen von Milton Werner
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.09.2008 | - |
| Vorstandsvorsitzender | 01.09.2008 | - | |
| Gründer | 01.09.2008 | - | |
| Präsident | 01.09.2008 | - | |
| Investor Relations Kontakt | 01.09.2008 | - | |
| Winship Cancer Institute | Corporate Officer/Principal | - | - |
Karriereverlauf von Milton Werner
Ehemalige bekannte Positionen von Milton Werner
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Celtaxsys, Inc.
 Celtaxsys, Inc. Pharmaceuticals: MajorHealth Technology Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA. | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2007 | 01.08.2007 |
| The Rockefeller University | Corporate Officer/Principal | 01.09.1996 | 01.06.2007 |
Ausbildung von Milton Werner
| University of California, Berkeley | Doctorate Degree |
| University of Southern California | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 7 |
Operativ
| Corporate Officer/Principal | 2 |
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
Sektoral
| Consumer Services | 4 |
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Celtaxsys, Inc.
Celtaxsys, Inc. Pharmaceuticals: MajorHealth Technology Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA. | Health Technology |
| Winship Cancer Institute |
- Börse
- Insiders
- Milton Werner
- Erfahrung
